California State Teachers Retirement System boosted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 28.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,337 shares of the company’s stock after acquiring an additional 5,874 shares during the period. California State Teachers Retirement System owned 0.07% of Stoke Therapeutics worth $887,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Royal Bank of Canada grew its stake in Stoke Therapeutics by 1,593.5% during the first quarter. Royal Bank of Canada now owns 1,304 shares of the company’s stock valued at $51,000 after acquiring an additional 1,227 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Stoke Therapeutics by 38.7% during the second quarter. Ameritas Investment Partners Inc. now owns 1,497 shares of the company’s stock valued at $50,000 after acquiring an additional 418 shares in the last quarter. Legal & General Group Plc grew its stake in Stoke Therapeutics by 35.7% during the second quarter. Legal & General Group Plc now owns 2,720 shares of the company’s stock valued at $92,000 after acquiring an additional 715 shares in the last quarter. Amundi purchased a new position in Stoke Therapeutics during the second quarter valued at $178,000. Finally, Virtus ETF Advisers LLC grew its stake in shares of Stoke Therapeutics by 7.9% in the 2nd quarter. Virtus ETF Advisers LLC now owns 5,786 shares of the company’s stock worth $195,000 after buying an additional 425 shares in the last quarter. 94.31% of the stock is owned by institutional investors.
STOK stock opened at $27.64 on Thursday. Stoke Therapeutics, Inc. has a 12-month low of $21.42 and a 12-month high of $71.58. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -13.22 and a beta of 0.20. The business’s 50-day moving average is $25.44 and its 200 day moving average is $29.64.
In other news, COO Huw M. Nash sold 5,700 shares of the business’s stock in a transaction that occurred on Friday, October 1st. The stock was sold at an average price of $24.83, for a total transaction of $141,531.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Huw M. Nash sold 3,800 shares of the business’s stock in a transaction that occurred on Monday, November 1st. The stock was sold at an average price of $23.54, for a total value of $89,452.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,100 shares of company stock worth $426,683. 51.80% of the stock is currently owned by insiders.
Several research firms have recently issued reports on STOK. JPMorgan Chase & Co. upgraded shares of Stoke Therapeutics from a “neutral” rating to an “overweight” rating and set a $41.00 target price for the company in a report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, September 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, November 9th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $60.25.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
See Also: Limitations to arbitrage trading
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.